We are a highly diversified global company. Our founders, biochemist Silvia Gold and psychiatrist Hugo Sigman, established in 1977 the first company of what today is Grupo Insud as an expansion of the family enterprise Roberto Gold funded in Argentina in 1943. They started working in the pharmaceutical business, the Group’s main activity, inspired by Roberto Gold. With time, Silvia and Hugo strengthened their activities in the pharmaceutical industry and expanded to a diversity of areas, including agribusiness, cultural industries, and nature and design, which today form the business ecosystem we work in.
Silvia Gold and Hugo Sigman open the first commercial office of Chemo, the Group’s first company, engaged in trading active pharmaceutical ingredients (APIs), in Barcelona, Spain.
Chemo founds Industriale Chimica in Italy, the Group’s first plant.
Chemo launches Romikin, its commercial office in Argentina focused on the development and manufacture of active ingredients for the pharmaceutical and veterinary industry. This office also has competencies in Uruguay, Paraguay and Bolivia.
Acquisition of Warner Lambert Química Sintética (España), the Group’s first chemical company with an FDA-approved site.
Start of operations in China.
Laboratorio Elea joins the Group, with its portfolio of Women’s Health, Oncology, Cardiology, Neuropsychiatry and Over-the-Counter products.
With the support of Dr. Roberto Gold, Mundo Sano is born: it is a civil-society organization that works to reduce the impact of so-called neglected tropical diseases (NTDs).
Projects start under the R&D+I Consortium, a public-private cooperation initiative focused on research, development and production of innovative medicines.
Chemo introduces its finished dosage form (FDF) business at its Liconsa plant, in Spain.
Agricultural activity begins with the acquisition of Los Murmullos cattle-breeding ranch in Chubut, Argentina.
Le Monde Diplomatique launches its Southern Cone edition in Argentina.
Chemo launches the marketing of branded medicines at global level.
Capital Intelectual, a publishing company devoted to the dissemination of culture and social analysis, is founded.
Forestry activity starts with the acquisition of the Shell plantation company in the north of Corrientes, Argentina.
Hugo Sigman and Oscar Kramer start filmmaking company Kramer & Sigman Films (K&S).
Solantu, a sustainable luxury brand specializing in research and marketing of unique objects in native wood and caiman leather, is created.
Chemo expands its industrial footprint to Asia and Latin America, with Chemo Wanbang and Chemway (China), Nosch (India) and Maprimed (Argentina).
Biogénesis and Bagó merge into Biogénesis Bagó, a company engaged in biotech and animal health, with Grupo Insud as shareholder.
Puerto Valle, a boutique hotel located on the banks of the Parana River with exclusive access to the Iberá Wetlands, opens its doors in Corrientes, Argentina.
Chemo gets FDA approval for its product plants in Spain (León Farma) and Italy (Industriale Chimica).
Mundo Sano starts operations in Spain with research, awareness-raising, diagnosis and treatment of Chagas disease in migrant communities.
Chemo lauches Ladee Pharma Research Institute (LPRI). LPRI’s focus globally is on innovative drug development.
Grupo Insud is founded, with the goal to integrate the diverse range of activities of the shareholders.
Chemo acquires Everett Laboratories and enters the American market.
Grupo Insud, Mundo Sano, ELEA, Maprimed and the Ministry of Health of Argentina form a public-private consortium to produce benznidazole to treat Chagas disease.
Pomera acquires Danzer Forestación and adds plantation assets in Misiones, Argentina.
Capital Intelectual expands its publishing business to Spain, under the brand Clave Intelectual.
Abarax© benznidazole tablets are registered by Elea in Argentina, enabling access to treatment to all patients affected by Chagas disease.
mAbxience, Chemo’s global brand specializing in R&D and the production of biosimilars is founded.
pharmADN, South America’s monoclonal antibody plant, opens in Argentina.
Sinergium Biotech, Latin America’s only plant to develop and produce vaccines and biotech medicines, opens in Argentina, with Grupo Insud as shareholder.
Chemo creates Exeltis, the new global brand for its prescription drugs.
Elea launches Vaxira, the first therapeutic vaccine for treatment of advanced lung cancer.
Mundo Sano celebrates its 20th anniversary and starts work in Ethiopia.
Mabxience acquires plant Genhelix in León, Spain, for the production of monoclonal antibodies.
Kramer & Sigman Films releases Wild Tales.
Capital Intelectual starts publishing Review. Revista de Libros.
Grupo Chemo changed its name to Insud Pharma. Under the new name, Insud Pharma is integrating three areas of business and well-known brands: Chemo, Exeltis and mAbxience. The new identity is the result of the evolution and diversification of the company.
Our name summarizes the values that set us apart. INSUD is an acronym for Innovation, Sustainability and Development. These values are deeply ingrained in our business principles, and inspire everything we do at the Group.
Innovation is our key driver to break with paradigms and transform reality.
We view development as an opportunity to energize our teams, reinvest, undertake new challenges and pursue excellence.
Our actions are guided by our interest in people, environmentally sustainable policies and giving back to society.
Creativity, a passion for doing, taking new challenges,
and looking ahead with optimism and proactivity are
the values underlying our vision.
We are a group of companies with a global presence, with a strong commitment to contribute to the development through long-term projects. Our lines of business are Life Sciences, Information & Culture, Agribusiness, and Nature & Design. The vision and style of our founders, Hugo Sigman and Silvia Gold, are present in every undertaking of the Group, demonstrating their wide range of interests and strong commitment to innovative and sustainable projects.